Join to View Full Profile
201 North Broadway StreetViragh BLDG 5th FLBaltimore, MD 21287
Phone+1 410-955-8964
Fax+1 410-367-2194
Dr. Yarchoan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Medical Oncology, 2016 - 2018
University of Pennsylvania Health SystemResidency, Internal Medicine, 2012 - 2015
Perelman School of Medicine at the University of PennsylvaniaClass of 2012
Certifications & Licensure
MD State Medical License 2015 - 2025
NC State Medical License 2021 - 2022
PA State Medical License 2012 - 2022
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers Start of enrollment: 2019 Mar 20
- National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer Start of enrollment: 2021 Jul 28
- DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma Start of enrollment: 2020 Apr 20
Publications & Presentations
PubMed
- Advances in radiation therapy for HCC: Integration with liver-directed treatments.Orly Yariv, Neil B Newman, Mark Yarchoan, Atoosa Rabiee, Bradford J Wood
Hepatology Communications. 2025-04-01 - Anti-CTLA4 therapy leads to early expansion of a peripheral Th17 population and induction of Th1 cytokines.Mari Nakazawa, Soren Charmsaz, Elsa Hallab, Mike Fang, Chester Kao
Cancer Immunology Research. 2025-03-27 - Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging.Marina Baretti, Soumya Shekhar, Vaibhav Sahai, Daniel Shu, Kathryn Howe
Hepatology Communications. 2025-03-01
Journal Articles
- Effects of B Cell–Activating Factor on Tumor ImmunityMark Yarchoan, MD, The Journal of Clinical Investigation
- Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology ClinicMark Yarchoan, Elizabeth Jaffee, Annals of Oncology
- Immuno-Oncology Trial Endpoints: Capturing Clinically Meaningful ActivityElad Sharon, Patrick M Forde, Valsamo Anagnostou, Hao Wang, Franco Verde, Mark Yarchoan, Clinical Cancer Research
Authored Content
- Effects of B Cell–Activating Factor on Tumor ImmunityMay 2020
Press Mentions
Lymph Node-like Structures May Trigger the Demise of Cancer TumoursOctober 30th, 2024- Tertiary Lymphoid Structures Linked to Improved Treatment Outcomes in Liver CancerOctober 28th, 2024
- Lymph Node-like Structures May Trigger the Demise of Cancer TumorsOctober 25th, 2024
- Join now to see all
Grant Support
- Neoadjuvant Immunotherapy Platform Study Reveals Mechanisms of Response in Hepatocellular Carcinoma (HCC)JOHNS HOPKINS UNIVERSITY2024–2029
- Exploiting A Critical Vulnerability To Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC)JOHNS HOPKINS UNIVERSITY2024–2029
- Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular CarcinomaJOHNS HOPKINS UNIVERSITY2023–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
